Drug Trial Radar · NCT05537142
A Study to Assess the Phamacokinetics of BV100 in Participants with Varying Degrees of Hepatic Impairment
Last checked: Nov 19, 2026Latest source record: Jan 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Sep 2, 2022
Primary completion
Jul 30, 2024
Study completion Oct 30, 2024
Sponsor
- Lead sponsor
- BioVersys AGIndustry
- Sponsor type
- Industry
- Collaborators
- Clinical Research Units Hungary
- First posted
- Sep 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To investigate the pharmacokinetics (PK) of rifabutin in subjects with hepatic impairment after single intravenous (IV) infusion of BV100
Conditions
- Healthy Participants
Interventions
BV100Drug
Rifabutin for Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To investigate the pharmacokinetics (PK) of rifabutin in participants with hepatic impairmentTime frame: 15 days
- To characterize the single dose pharmacokinetic profile of rifabutinTime frame: 15 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRU Hungary Kft., Early Phase Unit
Kistarcsa, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.